Evaluating miscarriage incidence after COVID-19 vaccination.

Area of Science:

• Reproductive Health
• Vaccinology
• Infectious Disease Epidemiology

Background:

• Pregnancy during COVID-19 infection may lead to adverse maternal outcomes.
• Understanding the safety of COVID-19 vaccines during pregnancy is crucial for public health.

Purpose of the Study:

• To evaluate the impact of COVID-19 vaccination on the risk of miscarriage.
• To assess the safety of specific COVID-19 vaccines (Sinopharm, Sputnik V, AZD1222, Barekat) in pregnant women.

Main Methods:

• A cohort study involving 26,701 women of reproductive age (15-49) vaccinated between April 2021 and August 2022 in Iran.
• Analysis focused on 459 pregnant women, followed until pregnancy completion.
• Miscarriage incidence rates were calculated and compared across different vaccine types.

Main Results:

• A total of 50 miscarriage cases were recorded among the 459 pregnant women.
• The cumulative incidence of miscarriage was 10.9% overall, with rates of 11.0%, 9.7%, 12.0%, and 11.1% for AZD1222, Sputnik V, Sinopharm, and Barekat vaccines, respectively.
• No statistically significant differences in miscarriage incidence were observed between the vaccine groups (P value = 0.962).

Conclusions:

• COVID-19 vaccination with Sputnik V, Sinopharm, Barekat, and AZD1222 does not appear to increase the probability of miscarriage.
• The studied COVID-19 vaccines demonstrate safety concerning miscarriage risk in pregnant women.
• Findings support the continued use of these vaccines in pregnant populations.